MX9709147A - Compuestos novedosos, preparacion y uso de los mismos. - Google Patents

Compuestos novedosos, preparacion y uso de los mismos.

Info

Publication number
MX9709147A
MX9709147A MX9709147A MX9709147A MX9709147A MX 9709147 A MX9709147 A MX 9709147A MX 9709147 A MX9709147 A MX 9709147A MX 9709147 A MX9709147 A MX 9709147A MX 9709147 A MX9709147 A MX 9709147A
Authority
MX
Mexico
Prior art keywords
preparation
novel
dolastatin derivatives
derivatives
novel dolastatin
Prior art date
Application number
MX9709147A
Other languages
English (en)
Inventor
Andreas Haupt
Franz Emling
Cynthia A Romerdahl
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Ag filed Critical Basf Ag
Publication of MX9709147A publication Critical patent/MX9709147A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

La presente invencion se refiere a los compuestos novedosos de la formula: R1R2N-CHX-CO-A-B-D-E-(F)t-K, en donde R1, R2, A, B, D, E, F, K, X, y t tienen los significados mencionados en la descripcion y se describe la preparacion de éstos. Las sustancias novedosas tienen efecto antineoplástico.
MX9709147A 1995-06-07 1996-06-03 Compuestos novedosos, preparacion y uso de los mismos. MX9709147A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/472,453 US5831002A (en) 1992-05-20 1995-06-07 Antitumor peptides
PCT/EP1996/002393 WO1996040752A1 (en) 1995-06-07 1996-06-03 Novel dolastatin derivatives, their preparation and use

Publications (1)

Publication Number Publication Date
MX9709147A true MX9709147A (es) 1998-03-31

Family

ID=23875567

Family Applications (2)

Application Number Title Priority Date Filing Date
MX9709146A MX9709146A (es) 1995-06-07 1996-06-03 Compuestos novedosos, preparacion y uso de los mismos.
MX9709147A MX9709147A (es) 1995-06-07 1996-06-03 Compuestos novedosos, preparacion y uso de los mismos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX9709146A MX9709146A (es) 1995-06-07 1996-06-03 Compuestos novedosos, preparacion y uso de los mismos.

Country Status (33)

Country Link
US (1) US5831002A (es)
EP (2) EP0832104B1 (es)
JP (2) JP3957751B2 (es)
KR (2) KR100437986B1 (es)
CN (2) CN1182154C (es)
AR (2) AR003136A1 (es)
AT (2) ATE223431T1 (es)
AU (2) AU725164B2 (es)
BG (2) BG102125A (es)
BR (2) BR9609424A (es)
CA (2) CA2219819C (es)
CO (2) CO4700527A1 (es)
CZ (2) CZ293683B6 (es)
DE (2) DE69623992T2 (es)
DK (2) DK0871656T3 (es)
ES (2) ES2188759T3 (es)
HR (2) HRP960257A2 (es)
HU (2) HU228071B1 (es)
IL (2) IL122216A (es)
MX (2) MX9709146A (es)
MY (2) MY119042A (es)
NO (2) NO317670B1 (es)
NZ (2) NZ310443A (es)
PL (2) PL185762B1 (es)
PT (2) PT832104E (es)
RO (2) RO119783B1 (es)
SI (2) SI0832104T1 (es)
SK (1) SK282466B6 (es)
TR (2) TR199701545T1 (es)
TW (2) TW508357B (es)
UA (2) UA46776C2 (es)
WO (2) WO1996040752A1 (es)
ZA (2) ZA964711B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807984A (en) * 1995-11-09 1998-09-15 Basf Aktienegesellschaft Oligopeptides, the preparation and use thereof
US20010009901A1 (en) * 1996-12-11 2001-07-26 Basf Aktiengesellschaft Germany Antineoplastic peptides
TW474946B (en) * 1995-12-15 2002-02-01 Basf Ag Novel compounds, the preparation and use thereof
US5965537A (en) * 1997-03-10 1999-10-12 Basf Aktiengesellschaft Dolastatin 15 derivatives with carbonyl and heterocyclic functionalities at the C-terminus
US6103698A (en) * 1997-03-13 2000-08-15 Basf Aktiengesellschaft Dolastatin-15 derivatives in combination with taxanes
US6143721A (en) * 1997-07-18 2000-11-07 Basf Aktiengesellschaft Dolastatin 15 derivatives
US6015790A (en) * 1997-10-06 2000-01-18 Basf Aktiengesellschaft Methods and compositions for treating rheumatoid arthritis
US5985837A (en) * 1998-07-08 1999-11-16 Basf Aktiengesellschaft Dolastatin 15 derivatives
CA2360740A1 (en) 1999-03-02 2000-09-08 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as reversible inhibitors of cathepsin s
US6420364B1 (en) 1999-09-13 2002-07-16 Boehringer Ingelheim Pharmaceuticals, Inc. Compound useful as reversible inhibitors of cysteine proteases
CA2385528C (en) 1999-10-01 2013-12-10 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
CN1307875C (zh) 2001-04-27 2007-04-04 宝洁公司 用于控制生物膜的化合物、组合物和方法
AU2002359792A1 (en) * 2001-12-18 2003-06-30 Proteologics, Inc. Methods and compositions for the inhibition of viral release
EP1531846A4 (en) * 2002-02-27 2006-04-19 Us Gov Health & Human Serv CONJUGATES OF LIGAND, LINK AND CYTOTOXIC AGENS, AND RELATED COMPOSITIONS AND USE PROCESSES
WO2006013552A2 (en) 2004-08-02 2006-02-09 Ramot At Tel Aviv University Ltd. Articles of peptide nanostructures and method of forming the same
WO2006122408A1 (en) 2005-05-18 2006-11-23 Aegera Therapeutics Inc. Bir domain binding compounds
CA2619568A1 (en) * 2005-08-19 2007-03-01 Government Of The United States Of America, Represented By The Secretary , Department Of Health And Human Services Topical formulations of histone deacetylase inhibitors and methods of using the same
US10004828B2 (en) * 2005-10-11 2018-06-26 Romat at Tel-Aviv University Ltd. Self-assembled Fmoc-ff hydrogels
US8163792B2 (en) 2006-05-16 2012-04-24 Pharmascience Inc. IAP BIR domain binding compounds
JP5452223B2 (ja) * 2006-07-24 2014-03-26 テトラロジック ファーマシューティカルズ コーポレーション Ｉａｐ阻害剤
PL2146719T3 (pl) * 2007-04-12 2013-12-31 Scinopharm Taiwan Ltd Sposób wytwarzania galantaminy
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
US8283372B2 (en) 2009-07-02 2012-10-09 Tetralogic Pharmaceuticals Corp. 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
ES2625637T3 (es) 2010-02-12 2017-07-20 Pharmascience Inc. Compuestos de unión al dominio BIR IAP
WO2012092409A2 (en) 2010-12-30 2012-07-05 Enanta Phararmaceuticals, Inc Macrocyclic hepatitis c serine protease inhibitors
EP2658858A4 (en) 2010-12-30 2014-06-25 Enanta Pharm Inc MACROCYCLIC INHIBITORS OF HEPATITIS C SERINE PROTEASE PHENANTHRIDINE
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
MX359217B (es) 2011-05-27 2018-09-19 Ambrx Inc Composiciones que contienen, métodos que involucran, y usos de derivados de dolastatina unidos a aminoácidos no naturales.
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
CA3230737A1 (en) 2021-09-03 2023-03-09 Toray Industries, Inc. Pharmaceutical composition for cancer treatment and/or prevention

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816444A (en) * 1987-07-10 1989-03-28 Arizona Board Of Regents, Arizona State University Cell growth inhibitory substance
US4879278A (en) * 1989-05-16 1989-11-07 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15
DE69230824T2 (de) * 1991-08-09 2000-07-27 Teikoku Hormone Mfg Co Ltd Neue tetrapeptidderivate
CA2136339C (en) * 1992-05-20 2008-02-05 Andreas Haupt Derivatives of dolastatin
US5504191A (en) * 1994-08-01 1996-04-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide methyl esters
US5530097A (en) * 1994-08-01 1996-06-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory peptide amides

Also Published As

Publication number Publication date
ZA964710B (en) 1997-12-08
ZA964711B (en) 1997-12-08
CA2219819A1 (en) 1996-12-19
JP3957751B2 (ja) 2007-08-15
MY119042A (en) 2005-03-31
IL122215A0 (en) 1998-04-05
DE69623992T2 (de) 2003-05-22
PL185762B1 (pl) 2003-07-31
AR003427A1 (es) 1998-08-05
CZ376597A3 (cs) 1998-06-17
WO1996040751A1 (en) 1996-12-19
HUP9801817A2 (hu) 1998-11-30
MX9709146A (es) 1998-03-31
NO975711L (no) 1998-01-30
IL122216A0 (en) 1998-04-05
AU725164B2 (en) 2000-10-05
AU6124296A (en) 1996-12-30
WO1996040752A1 (en) 1996-12-19
SK165397A3 (en) 1998-10-07
PT832104E (pt) 2002-12-31
CA2219819C (en) 2008-05-20
HU228071B1 (hu) 2012-09-28
TR199701544T1 (xx) 1998-03-21
NO975711D0 (no) 1997-12-05
CZ376397A3 (cs) 1998-06-17
CA2219818C (en) 2008-05-20
PT871656E (pt) 2002-12-31
BR9609423A (pt) 1999-06-29
UA46775C2 (uk) 2002-06-17
CZ293682B6 (cs) 2004-07-14
ES2186783T3 (es) 2003-05-16
HUP9801910A3 (en) 1999-06-28
AU6124196A (en) 1996-12-30
JPH11504653A (ja) 1999-04-27
DE69623472D1 (de) 2002-10-10
NZ310443A (en) 1999-10-28
NO317670B1 (no) 2004-11-29
EP0832104B1 (en) 2002-09-04
HU228073B1 (hu) 2012-09-28
AR003136A1 (es) 1998-07-08
BR9609424A (pt) 2000-03-28
KR19990022583A (ko) 1999-03-25
SI0871656T1 (en) 2003-08-31
HRP960257A2 (en) 1998-02-28
TW424096B (en) 2001-03-01
NO318384B1 (no) 2005-03-14
KR100437985B1 (ko) 2004-09-18
SK282466B6 (sk) 2002-02-05
TR199701545T1 (xx) 1998-04-21
DE69623992D1 (de) 2002-10-31
CO4700527A1 (es) 1998-12-29
IL122216A (en) 2002-02-10
RO119783B1 (ro) 2005-03-30
ATE223431T1 (de) 2002-09-15
RO118953B1 (ro) 2004-01-30
NO975710L (no) 1998-02-02
BG102125A (en) 1998-09-30
CN1187198A (zh) 1998-07-08
DK0832104T3 (da) 2003-01-06
EP0871656B1 (en) 2002-09-25
ATE224910T1 (de) 2002-10-15
BG102152A (en) 1998-09-30
IL122215A (en) 2001-08-26
KR100437986B1 (ko) 2004-09-18
CN1187199A (zh) 1998-07-08
JP4221062B2 (ja) 2009-02-12
HUP9801817A3 (en) 1999-06-28
PL323726A1 (en) 1998-04-14
DE69623472T2 (de) 2003-08-21
HRP960277A2 (en) 1997-10-31
CZ293683B6 (cs) 2004-07-14
EP0871656A1 (en) 1998-10-21
UA46776C2 (uk) 2002-06-17
EP0832104A1 (en) 1998-04-01
SI0832104T1 (en) 2003-08-31
AU725170B2 (en) 2000-10-05
MY124487A (en) 2006-06-30
ES2188759T3 (es) 2003-07-01
CN1182154C (zh) 2004-12-29
PL323723A1 (en) 1998-04-14
TW508357B (en) 2002-11-01
US5831002A (en) 1998-11-03
KR19990022582A (ko) 1999-03-25
CO4700526A1 (es) 1998-12-29
NZ310444A (en) 1999-11-29
CA2219818A1 (en) 1996-12-19
HUP9801910A2 (hu) 1999-01-28
CN1182153C (zh) 2004-12-29
NO975710D0 (no) 1997-12-05
DK0871656T3 (da) 2003-01-27
JPH11504652A (ja) 1999-04-27
PL185763B1 (pl) 2003-07-31

Similar Documents

Publication Publication Date Title
MX9709147A (es) Compuestos novedosos, preparacion y uso de los mismos.
PL309353A1 (en) Novel peptides, method of obtaining them and their application
IL124674A0 (en) Piperazine derivatives pharmaceutical compositions containing the same and use thereof
MY132115A (en) Novel thrombin inhibitors
MY132820A (en) Novel thrombin inhibitors
MX9704030A (es) 1,1-dioxidos de 2-heterocicliloxi y tiometil-1,2,5-tiadiazolidin-3-ona y composiciones y metodo de uso de los mismos.
HUP9600256A3 (en) Substituted diphenyl-sulfonamide endothelin antagonists, pharmaceutical compositions containing the same and their medical uses
HUT71398A (en) Derivatives of dolastatin
WO1996032403A3 (de) Neue cytosin- und cytidinderivate
MX9704034A (es) Derivados y composiciones de 1,1-dioxido de 2-arilcarboniloximetil-1,2,5-tiadiazolidin-3-ona substituido y metodo de uso.
BG98238A (en) Substituted benzothiazole derivatives, methods for their preparation and their application as herbicides
NZ324691A (en) Antineoplastic peptides
AU3416995A (en) Endothelin receptor antagonists
MX9800053A (es) Herbicidas de cis-2,3-expoxicicloalcanol bencilado.